When there's no room to grow

Heidi Ledford

Nature, 2008, vol. 454, issue 7201, 144-145

Abstract: To maintain profits in the face of rising development costs and slow drug pipelines, big pharmaceutical firms are trying to cut back. Heidi Ledford examines how GlaxoSmithKline has tried to adapt.

Date: 2008
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/454144a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:454:y:2008:i:7201:d:10.1038_454144a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/454144a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().